SGTL2 inhibitors and amputations in the US FDA Adverse Event Reporting System

The Lancet Diabetes and Endocrinology

Volumn 5, Issue 9, 2017, Pages 680-681

  Fadini, Gian Paolo ^a   Avogaro, Angelo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EMPAGLIFLOZIN; ORAL ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

AMPUTATION; CLINICAL PRACTICE; DIABETIC FOOT; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG SURVEILLANCE PROGRAM; HUMAN; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK REDUCTION; SIDE EFFECT; TREATMENT DURATION; TREATMENT INDICATION; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); COMPLICATION; FOOD AND DRUG ADMINISTRATION; RISK FACTOR; STATISTICS AND NUMERICAL DATA; UNITED STATES;

AMPUTATION; CANAGLIFLOZIN; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85024835007     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30257-7     Document Type: Letter

References (4)

1. Neal, B, Perkovic, V, Mahaffey, KW, et al., for the CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med, 2017 published online June 12. DOI:10.1056/NEJMoa1611925.
2. Fadini, GP, Bonora, BM, Avogaro, A, SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia 60 (2017), 1385–1389.
3. Sarangdhar, M, Tabar, S, Schmidt, C, et al. Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data. Nat Biotechnol 34 (2016), 697–700.
4. Hippisley-Cox, J, Coupland, C, Diabetes treatments and risk of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia: open cohort study in primary care. BMJ, 352, 2016, i1450.